Peshkova / Shutterstock.com
LSIPR’s Sarah Morgan investigates the current state of play of M&A in the sector and predicts the next year of activity.
Deal-making experienced a lull over the winter period last year, but this was the calm before the storm. A January 3 announcement from US pharmaceutical company Bristol-Myers Squibb (BMS) reignited a stream of mergers and acquisitions (M&A) activity in the life sciences space.
BMS revealed it would purchase Celgene, a drug manufacturer focusing on new cancer and inflammation treatments, for $74 billion.
It marked the start of a busy 2019, and was the first of seven megadeals (deals valued at $5 billion plus) announced in the first half of this year, according to PwC.
Life Sciences Intellectual Property Review (LSIPR) tracks the increasing challenges for intellectual property specialists in the rapidly evolving world of life sciences. From gene patents to stem cell research, we provide the very best news and analysis.
To continue reading this article and to access 4,500+ articles, our digital magazines and special reports published for LSIPR subscribers only then you will need a subscription.
If you are already subscribed please login.
Official LSIPR subscribers include:
Allen & Overy
Arnold & Siedsma
Birch, Stewart, Kolasch & Birch LLP (BSKB)
Carpmaels & Ransford
Cooley
European Patent Office
Finnegan LLP
GH Research
Gowling WLG
George Washington Law School
HGF Limited
IQVIA
Kirkland & Ellis International LLP
Marks & Clerk
Mintz Levin
NiKang Therapeutics Inc.
Powell Gilbert LLP
Procopio, Cory, Hargreaves & Savitch LLP
Taylor Wessing
The United States Patent and Trademark Office (USPTO)
Valea AB
World Intellectual Property Office
For multi-user price options, or to check if your company has an existing subscription we can add you into for FREE, please contact Atif at achoudhury@newtonmedia.co.
If you have any technical issues please email tech support.
M&A, life sciences, drug manufacturer, Celgene, megadeals, oncology, pharmaceuticals, AI, machine learning, innovative therapies, R&D, CAR-T, Brexit, tech
